UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

Zinger Key Points

HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating on UroGen Pharma Ltd. URGN from Buy to Neutral.

Selvaraju points out that the FDA’s Oncologic Drugs Advisory Committee voted 5-4 against the benefit-risk profile of UroGen’s investigational therapy UGN-102 (mitomycin for intravesical solution), intended for patients with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC).

According to the analyst, the narrow negative vote significantly lowers the likelihood of UGN-102 receiving timely approval.

Also Read: UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates

Selvaraju notes that if UGN-102 does receive FDA approval next month — with the only condition being a post-marketing randomized, controlled trial — this scenario would warrant a reassessment of their current rating on the stock.

Selvaraju notes that UroGen concluded the first quarter of 2025 with approximately $200 million in cash, cash equivalents and marketable securities.

According to the analyst, this financial position should be adequate to sustain operations through late 2026, even if UGN-102 fails to secure regulatory approval.

For 2026, the analyst now forecasts a net loss of $2.14 per share, a notable shift from his earlier projection of 27 cents in earnings for the year.

Selvaraju highlights that UroGen is advancing development on UGN-103 and UGN-104, next-generation mitomycin-based formulations for UGN-102 and JELMYTO, respectively.

These candidates combine the company’s RTGel delivery platform with a novel mitomycin formulation licensed from medac GmbH.

The Phase 3 UTOPIA trial evaluating UGN-103 in patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer is currently enrolling.

Selvaraju anticipates that enrollment will wrap up by mid-2025, with top-line data expected shortly after. If results are positive, a regulatory submission could occur in 2026, potentially leading to FDA approval by 2027.

URGN Price Action: Urogen shares closed at $4.19 on Friday.

Loading...
Loading...

Read Next:

Photo: Shutterstock

URGN Logo
URGNUroGen Pharma Ltd
$3.95-5.73%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
4.36
Growth
Not Available
Quality
Not Available
Value
27.38
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Comments
Loading...